AcadeMab Biomedical Co., Ltd., team members specialize in protein drugs, especially anti-cancer antibody drug development platforms and technologies. Our company can independently develop antibodies or provide high-quality, competitive products required by domestic and foreign protein-drug and antibody development companies. Our goal is to become a world-class new antibody drug research and development company. The foundation of AcadeMab Biomedical is its antibody development technology platforms, which include a phage-display fully human antibody library and human antibody-producing transgenic mice. These platforms can be applied to develop antibody products and optimize antibody drugs, including both novel and humanized antibodies. Among the antibody products that we have developed, our humanized anti-EpCAM antibody (hEpAb2-6) shows excellent anti-tumor potential and is well-positioned in terms of worldwide patent protections. The target of this drug, EpCAM, is highly expressed on the surface of solid tumor cells. Importantly, the hEpAb2-6 product is the only anti-EpCAM antibody in the world able to directly induce apoptosis in cancer cells.